Evidence map›Paper›PMID 35078538›Full record

ArticleBioelectronic medicine2022

Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of pediatric nephrotic syndrome: a pilot study.

Kumail Merchant, Stavros Zanos, Timir Datta-Chaudhuri, Clifford S Deutschman, Christine B Sethna

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioelectronic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04169776 (Effect of Daily Transcutaneous Auricular Vagus Nerve), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04169776 nacompletednot on this map

Effect of Daily Transcutaneous Auricular Vagus Nerve (taVNS) Stimulation on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

TypeinterventionalSponsorNorthwell HealthRan2019 to 2021Enrolled7ConditionsIdiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic SyndromeArmsTranscutaneous Auricular Vagus Nerve (taVNS) stimulation
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Clinical perspectives on vagus nerve stimulation: present and future.Clinical science (London, England : 1979) · 2022
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kumail MerchantCohen Children's Medical Center of New York, New Hyde Park, United States, NY.
Stavros ZanosThe Feinstein Institutes for Medical Research, Manhasset, United States, NY.
Timir Datta-ChaudhuriThe Feinstein Institutes for Medical Research, Manhasset, United States, NY.
Clifford S DeutschmanCohen Children's Medical Center of New York, New Hyde Park, United States, NY.
Christine B SethnaCohen Children's Medical Center of New York, New Hyde Park, United States, NY. csethna@northwell.edu.
Feinstein Institute for Medical Research · USCohen Children's Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildren with frequently relapsing nephrotic syndrome (FRNS) and steroid resistant nephrotic syndrome (SRNS) are exposed to immunosuppressant medications with adverse side effects and variable efficacy. Transcutaneous auricular vagus nerve stimulation (taVNS) modulates the immune system via the inflammatory reflex and has become a therapy of interest for treating immune-mediated illnesses.

methodsAn open-label, pilot study of tavNS for five minutes daily for 26 weeks via a TENS 7000 unit was conducted.

resultsThree FRNS participants and 4 SRNS participants had a mean age of 9.5±4.2 years (range 4 to 17). Those with FRNS remained relapse-free during the study period; two participants continued treatment and remained in remission for 15 and 21 months, respectively. Three SRNS participants experienced a reduction in first morning UPC (mean of 42%, range 25-76%). Although UPC decreased (13.7%) in one SRNS participant with congenital nephrotic syndrome, UPC remained in nephrotic range. All but one participant (non-compliant with treatment) experienced a reduction in TNF (7.33pg/mL vs. 5.46pg/mL, p=0.03). No adverse events or side effects were reported.

conclusionstaVNS was associated with clinical remission in FRNS and moderately reduced proteinuria in non-congenital SRNS. Further study of taVNS as a treatment for nephrotic syndrome in children is warranted. ClinicalTrials.gov Identifier: NCT04169776, Registered November 20, 2019, https://clinicaltrials.gov/ct2/show/NCT04169776 .

Indexed as

ChildrenFocal segmental glomerular sclerosisMinimal change diseaseNephrotic syndrometaVNSVagus nerve stimulation

Identifiers

PMID35078538
PMCPMC8790887
OpenAlexW4210656850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.